Donate

Avaxia cleared to start human trials of oral antibody for Crohns Disease

Home»Health»Intestinal Disease»Crohns»Avaxia cleared to start human trials of oral antibody for Crohns Disease

Avaxia cleared to start human trials of oral for Crohns disease, ulcerative colitis

A 7-year-old that’s developed a new way to create and deliver an old kind of drug is making the to the clinical stage as it prepares to take its drug for Crohn’s disease and ulcerative colitis into human trials.

The U.S. has cleared the IND application filed by Avaxia , which develops orally administered antibody drugs that act on biological targets located in the . Its lead product, AVX-470, was designed to neutralize the effects of an established target for called (PDF).

Antibodies are proteins, so they’re digestible, which is why antibody drugs like Janssen’s Remicade and ’ Humira are injected, Avaxia vice president of corporate development explained. Avaxia’s antibodies, he continued, are “engineered by nature to resist digestion.” They’re generated in dairy cows and isolated from the cows’ early milk.

Read more:

Avaxia cleared to start human trials of oral antibody for Crohn’s disease
News
A 7-year-old pharmaceutical company that’s developed a new way to create and deliver an old kind of drug is making the critical transition to the clinical stage as it prepares to take its drug for Crohn’s disease and ulcerative colitis into human

You must be logged in to post a comment Login

No Guts Know Glory

IDEAS Kids

IDEAS Kids

IBD Adventures